AT1001 for the Treatment of COVID-19 Related MIS-C
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo
in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are
at high risk of progression.
AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) or matching placebo
will be administered orally four times a day (QID) to the standard of care for MIS-C.